Marquette University

e-Publications@Marquette
Physical Therapy Faculty Research and
Publications

Physical Therapy, Department of

5-2017

Effects on Breathing of Agonists to μ-opioid
-opioid or GABAA Receptors
Dialyzed into the Ventral Respiratory Column of Awake and
Sleeping Goats
Thomas M. Langer III
Medical College of Wisconsin

Suzanne E. Neumueller
Medical College of Wisconsin

Emma Crumley
Medical College of Wisconsin

Nicholas J. Burgraff
Medical College of Wisconsin

Sawan Talwar
Medical College of Wisconsin

See next page for additional authors
Follow this and additional works at: https://epublications.marquette.edu/phys_therapy_fac
Part of the Physical Therapy Commons

Recommended Citation
Langer, Thomas M. III; Neumueller, Suzanne E.; Crumley, Emma; Burgraff, Nicholas J.; Talwar, Sawan;
Hodges, Matthew R.; Pan, Lawrence; and Forster, Hubert V., "Effects on Breathing of Agonists to μ-opioid
or GABAA Receptors Dialyzed into the Ventral Respiratory Column of Awake and Sleeping Goats" (2017).

Physical Therapy Faculty Research and Publications. 147.
https://epublications.marquette.edu/phys_therapy_fac/147

Authors
Thomas M. Langer III, Suzanne E. Neumueller, Emma Crumley, Nicholas J. Burgraff, Sawan Talwar,
Matthew R. Hodges, Lawrence Pan, and Hubert V. Forster

This article is available at e-Publications@Marquette: https://epublications.marquette.edu/phys_therapy_fac/147

Marquette University

e-Publications@Marquette
Physical Therapy Faculty Research and Publications/College of Health
Sciences
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The
published version may be accessed by following the link in the citation below.

Respiratory Physiology & Neurobiology, Vol. 239 (May, 2017): 10-25. DOI. This article is © Elsevier and
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not
grant permission for this article to be further copied/distributed or hosted elsewhere without the
express permission from Elsevier.

Contents
Keywords ....................................................................................................................................................................3
Highlights ..................................................................................................................... Error! Bookmark not defined.
Abstract ......................................................................................................................................................................3
1. Introduction ............................................................................................................................................................3
2. Methods .................................................................................................................................................................4
2.1. Goats................................................................................................................................................................4
2.2. Surgical procedures .........................................................................................................................................5
2.3. Physiological studies ........................................................................................................................................6
............................................................................................................................................................................8
2.4. Neurochemical analyses ..................................................................................................................................9
2.5. Data and statistical analyses ...........................................................................................................................9
2.6. Neurochemical analysis ................................................................................................................................ 10
3. Results ................................................................................................................................................................. 10
3.1. Placement of microtubules (MTs) ................................................................................................................ 10
3.2. DAMGO microdialysis ................................................................................................................................... 11
3.3. Muscimol microdialysis ................................................................................................................................ 23

4. Discussion ............................................................................................................................................................ 26
4.1. Ventilatory and neurochemical effects of opioids dialyzed into the VRC .................................................... 26
4.2. Ventilatory and neurochemical effects of unilateral muscimol dialysis in the VRC ..................................... 28
4.3. μ-Opioid and GABA receptor-mediated breathing instabilities ................................................................... 28
5. Caveats and limitations ....................................................................................................................................... 28
6. Summary and conclusions ................................................................................................................................... 29
Author contributions ............................................................................................................................................... 29
Disclosures ............................................................................................................................................................... 29
References ............................................................................................................................................................... 30

Effects on Breathing of Agonists to μ-opioid or GABAA Receptors
Dialyzed into the Ventral Respiratory Column of Awake and
Sleeping Goats
Thomas M. Langer III

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Suzanne E. Neumueller

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Emma Crumley

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Nicholas J. Burgraff

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Sawan Talwar

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Matthew R. Hodges

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI
Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI

Lawrence Pan

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI

Hubert V. Forster

Department of Physiology, Medical College of Wisconsin, Milwaukee, WI
Department of Physical Therapy, Marquette University, Milwaukee, WI
Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI
Zablocki Veterans Affairs Medical Center, Milwaukee, WI

Keywords

Breathing, Neuromodulation, μ-Opioids, GABAA, Ventral respiratory column, Sleep

Abstract
Pulmonary ventilation (V� I) in awake and sleeping goats does not change when antagonists to several excitatory
G protein-coupled receptors are dialyzed unilaterally into the ventral respiratory column (VRC). Concomitant
changes in excitatory neuromodulators in the effluent mock cerebral spinal fluid (mCSF) suggest
neuromodulatory compensation. Herein, we studied neuromodulatory compensation during dialysis of agonists
to inhibitory G protein-coupled or ionotropic receptors into the VRC. Microtubules were implanted into the VRC
of goats for dialysis of mCSF mixed with agonists to either μ-opioid (DAMGO) or GABAA (muscimol) receptors.
We found: (1) V� I decreased during unilateral but increased during bilateral dialysis of DAMGO, (2) dialyses of
DAMGO destabilized breathing, (3) unilateral dialysis of muscimol increased V� I, and (4) dialysis of DAMGO
decreased GABA in the effluent mCSF. We conclude: (1) neuromodulatory compensation can occur during
altered inhibitory neuromodulator receptor activity, and (2) the mechanism of compensation differs between G
protein-coupled excitatory and inhibitory receptors and between G protein-coupled and inotropic inhibitory
receptors.

1. Introduction
From invertebrates to mammals, the excitability of neural circuits that govern motor outputs depends largely
upon the local levels of excitatory and inhibitory neuromodulators. However, the mechanisms that regulate the
local release of neuromodulators, or compensatory shifts in second messengers downstream of
neuromodulatory receptors remain unclear. Gaining insight into regulation of neuromodulation is important to
improve treatment of disorders such as epilepsy, depression, and Parkinson’s disease, as well as opioid induced
respiratory depression; thus, there is a need for studies on control of neuromodulators.
Data from rodent models suggests there is “neuromodulator interdependence”, whereby changes in the activity
of one or more neuromodulatory receptors are compensated by changes in the release of other
neuromodulators to maintain stable ventilation (Doi and Ramirez, 2008, Doi and Ramirez, 2010). This concept
has also been studied in awake and sleeping goats by dialyzing atropine (50 mM) unilaterally into the ventral
respiratory column (VRC) to reduce or block excitatory muscarinic receptor activity (Muere et al., 2013). Rather
than a hypothesized decrease in pulmonary ventilation (V� I) and breathing frequency (f), atropine dialysis
increased f and V� I (Muere et al., 2013) which could have been due to increases in the excitatory
neuromodulators substance P (SP) and serotonin (5-HT) as measured in the effluent dialysate. Subsequent
studies in this goat model found that a lower dose of atropine (5 mM), or selective M2 (methoctramine) or M3
(4-DAMP) receptor antagonists had no effect on f and V� I, but increased SP in the effluent dialysate to a lesser
extent than 50 mM atropine (Muere et al., 2015a). Moreover, dialysis into the VRC of antagonists to excitatory
SP receptors (neurokinin-1; NK-1) or 5-HT receptors (5-HT2A) alone or in combination with 5 mM atropine did not
affect f and V� I, but increased SP and decreased GABA in effluent dialysate (Muere et al., 2015b). These findings
suggest that presumptive decreases in activity of one or more excitatory receptors are accompanied by changes
in other neuromodulators to maintain f and V� I in awake and NREM sleep states which supports the concept of
neuromodulator interdependence (Doi and Ramirez, 2008). In other words, there is “compensation” defined as

no change in ventilation with dialysis of excitatory antagonists and that this may be due to the observed
concomitant increase in excitatory (SP) and decrease in inhibitory neurotransmitters (GABA).
The studies above examined the effects of blocking excitatory, G protein-coupled neuromodulatory receptors. It
is unknown whether increased activation of inhibitory receptors in the VRC will also elicit compensatory changes
in neuromodulators and/or affect f and V� I. Widely expressed in the VRC are μ-opioid inhibitory receptors (Krause
et al., 2009a, Pattinson, 2008), which are also G protein-coupled receptors (GPCRs). When activated, μ-opioid
receptors act through second messenger cascades to reduce intracellular calcium and increase potassium efflux
to decrease cellular activity (Pattinson, 2008). Administration of μ-opioid receptor agonists to the preBӧtzinger
Complex (preBӧtC) region of the VRC has, in some studies, caused respiratory depression (Montandon and
Horner, 2014, Montandon et al., 2011, Pattinson, 2008). However, other studies found that eupneic breathing is
unchanged (Krause et al., 2009a) or increased with μ-opioid receptor agonists administration to the
preBӧtC/VRC (Mustapic et al., 2010). The absence of a depression of breathing with increased μ-opioid receptormediated inhibition could be due to neuromodulatory compensation.
Another endogenous inhibitory neuromodulator controlling breathing is ϒ-aminobutyric acid (GABA) acting at
GABAB metabotropic receptors to regulate neuronal membrane potential. However, acting through GABAA
ionotropic receptors, GABA also directly affects neuronal activity by altering intracellular chloride (Tillakaratne et
al., 1995). It is unknown whether neuromodulator interdependence occurs when the activity of ionotropic
receptors is altered, and whether compensation occurs by similar or different mechanisms to increases in
inhibitory signaling through GPCRs.
Herein we studied whether neuromodulatory compensation occurs in response to increased inhibitory receptor
activity by unilaterally dialyzing the μ-opioid receptor agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)
or the GABAA receptor agonist muscimol into the VRC while measuring breathing and neurochemicals in the
effluent dialysate of awake and sleeping goats. We chose these inhibitory agonists due to lack of agreement
among several previous studies on effects on respiratory control of these agonists (Curran et al., 2000, Gatti et
al., 1987, Krause et al., 2009a, Lalley, 2003, Lalley, 2008, Montandon et al., 2011, Mustapic et al., 2010, Nattie
and Li, 2000, Taylor et al., 2006, Yamada et al., 1981, Yamada et al., 1982). We hypothesized that f and V� I would
not change during DAMGO or muscimol dialysis, but that there would be changes in neurochemicals in the
effluent dialysate. We also hypothesized that the mechanism of compensation would differ between
antagonism of GPCR and ionotropic receptors.
Through bilateral dialysis of DAMGO, we also tested the hypothesis that increased activity of the contralateral
VRC may contribute to the stable f and V� I during unilateral DAMGO dialysis. We did not test this same
hypothesis for muscimol because of the large ventilatory and behavioral responses observed in some goats with
unilateral muscimol dialysis (see Results).

2. Methods
2.1. Goats
Fifteen adult female, non-pregnant goats with an average body weight of 51.0 +/− 8.5 kg were housed and
studied in an environmental chamber with a fixed ambient temperature and alternating 12-h light-dark cycles
set between 7am and 7pm. There was free access to food and water except for study periods and the 24 h
preceding surgeries. All protocols and procedures utilized in this study were approved by the Medical College of
Wisconsin Institutional Animal Care and Use Committee.

2.2. Surgical procedures
The goats were anesthetized with ketamine (IV), intubated, and mechanically ventilated with isoflurane in 100%
oxygen for the duration of the surgery. Flunixin meglumine (2 mg/kg, IM) was administered once pre-operatively
and for two days post-operatively for pain. To minimize infection, ceftriaxone (25 mg/kg, IV) in 100 mL saline
was administered over 30 min twice daily at 8–12 h intervals for three days starting the morning of a craniotomy
surgery. Subsequently, ceftiofur sodium (4 mg/kg, IM) and gentamycin (6 mg/kg, IM) were administered once
daily for the remainder of the study period. To minimize intracranial edema following the craniotomy,
dexamethasone (4 mg/mL, IV) was administered three times daily and tapered for a week following surgery.
Surgical sites were treated daily for 7 days with triple antibiotic ointment. Rectal temperature (TR), heart rate
(HR), and oxygen saturation were continuously monitored during surgery. Over the following 24 post-operative
hours these variables were monitored at predetermined intervals.
Under sterile conditions, two surgeries were performed separated by two weeks. During one surgery, an incision
was made in the goat’s neck to locate the carotid artery which was subsequently dissected out, elevated to
beneath the skin, and sutured to the overlaying skin before closing the incision. Also, electroencephalographic
(EEG) and electrooculographic (EOG) electrodes were inserted into the midline cranium and the superior orbital
ridge for recordings to score wakefulness/sleep during night studies. The electrodes were attached to screws,
secured with dental acrylic, and the wires were pulled through the skin prior to closure of the incision.
In a second surgery two weeks later, stainless steel microtubules (70.0 mm length, 1.27 mm outer diameter,
0.84 mm inner diameter) were chronically implanted unilaterally (n = 3) or bilaterally (n = 12) into or near the
preBӧtC of the VRC (Fig. 1A & B). An incision was made that bisected the nuchal ligament along the dorsal
midline of the skull and neck. A rotary drill was used to create an occipital craniotomy for visualization of the
dura which, when opened, exposed the dorsal medulla. Obex served as an anatomical reference for
micromanipulator controlled microtubule placement into the VRC. The target for placement was the preBӧtC
which in goats is approximately 2.5–3.5 mm rostral from obex, 4.0–5.0 mm lateral from the midline and 4.0–
6.0 mm from the dorsal surface of the medulla (Krause et al., 2009a, Wenninger et al., 2004). However, in some
cases adjustments in microtubule placement had to be made to avoid blood vessels. Following microtubule
placement, screws were inserted into the skull to which the microtubules were chronically secured using dental
acrylic. Stainless steel stylets, slightly shorter than the microtubules, were inserted into the microtubules and
the incisions sutured closed. Following the procedure, post-operative monitoring and medications were
administered as described above.

Fig 1. A and B show sections of the goat medulla at two rostral to caudal distances from obex depicting the microtubule
location in which DAMGO or muscimol were dialyzed unilaterally (1A) and bilaterally (1B). Each goat was numbered for
unilateral and bilateral studies, and the numbers for the left and right microtubule are located in the images where the
distal end of the microtubule was identified by post mortem histological analysis. The 0.5 mm wide porous membrane of
the dialysis probe extended 2 mm beyond the distal end of the microtubule; thus, we inserted a 2 mm long, 1 mm wide
gray filled rectangle for each number to represent a conservative estimate of the region of diffusion of the dialyzed
substances (see text for basis of minimal diffusion). The circle in each image is the approximate location of the VRC in goats.
The inset in 1A and 1B is the quantitation of the breathing frequency responses to mCSF and NMDA (mCSF/NMDA)
injections displayed as percent of control. Goats number 7 and 10 were included in both groups of studies.

2.3. Physiological studies
The goats were acclimated to study protocols and equipment during the weeks of recovery from surgery. To
obtain ventilatory data, a custom fitted mask was secured to the goat’s muzzle. A two-way breathing valve was
inserted into the front of the mask with hoses attached to the inlet and outlet of the valve. For all studies,
normal room air was inhaled though the inlet hose which was attached to a pneumotachograph connected to a
computer. Windaq data acquisition software was utilized for breath-by-breath recording of inspiratory flow for
computation of inspiratory (TI) and expiratory (TE) time, breathing frequency (f), tidal volume (VT), mean
inspiratory flow rate (VT/TI) and inspiratory minute ventilation (V� I). The outlet hose was attached to a Tissot
spirometer for collection of expired air (the volume of which was measured at 5 min intervals). Expired air was
analyzed for O2 and CO2 concentration and those values were used to calculate O2 consumption and CO2
excretion. In several goats, heart rate (HR) and blood pressure (BP) were recorded via an indwelling catheter
secured in the elevated carotid artery (which also facilitated blood sampling). Arterial blood samples were
analyzed for pH, paCO2, paO2, and O2 saturation using a Siemens RapidLab248 blood gas analyzer. For
night/sleep studies, the only change was the addition of EEG and EOG wires attached to the implanted
electrodes. Rectal temperature was routinely recorded.

Dialysis probes (Harvard Apparatus, formerly CMA microdialysis, Holliston MA) inserted into the microtubules
were 72 mm in length, 70 mm of which is a stainless-steel tube and the final 2 mm is a semi-permeable
membrane (membrane diameter 0.5 mm, 20kda cut-off, 3 μL internal volume). Only the 2 mm membrane
penetrated the brain tissue. During studies, the perfusate was either mock cerebral spinal fluid (mCSF: 124 mM
NaCl, 2.0 mM KCL, 2.0 mM MgCl2, 1.3 mM K2PO4, 2.0 mM CaCl2, 11 mM glucose, 26 mM NaHCO3− and pH 7.32 in
sterile distilled H2O) alone or with the μ-opioid agonist DAMGO (10, 50 or 100 μM, Sigma-Aldrich: E7384) or the
GABAA agonist muscimol (0.5, 1.0, or 10.0 mM, Abcam: ab120094). The solutions were prepared in a tonometer
flask, warmed to 39 °C, and equilibrated with 6.4% CO2 and 12% O2 balance N2. A syringe pump (Harvard
Apparatus) delivered the dialysate to the dialysis probe at a flow rate of 25 μL/min. To minimize distraction of
the goat, the pump was outside of the chamber; thus, a 150 cm length of polypropylene tubing (PE50) was
needed to connect the syringe to the probe. The length of the tubing caused a delay of about 20 min between
the start of dialysis and the arrival of perfusate at the probe tip. Moreover, during the initial 15–20 min of hour
three, drug delivery to the tissue would continue as in hour 2. In addition, thereafter washout of the drug from
the tissue would be time-dependent. As a result, the temporal pattern of ventilatory responses (shown in
Figures and Tables) likely reflect these drug delivery and washout characteristic. To collect effluent dialysate, a
short length of tubing was attached to the outlet end of the probe which was then attached to a modified
cryotube. Separate tubes were used for effluent collection during each hour of dialysis. The effluent was then
aliquoted and frozen at −80 °C for subsequent analysis by department biochemical core lab facilities.
We performed uni- and bilateral dialysis of DAMGO, but dialysis of muscimol was only unilateral for reasons
stated in the introduction. Provided in Table 1 is a list of studies which were completed on each of the 15 goats.
Thirty minutes after probe insertion, we collected data over a fifteen-minute pre-dialysis control period which
was followed by three continuous hours of dialysis. Hour 1 was mCSF alone, hour 2 was mCSF alone or mCSF
mixed with a drug, and hour 3 was again mCSF alone. DAMGO dialysis was at concentrations of 10, 50, or
100 μM which is over the range and duration others used in dialyses studies on rats or dogs (Montandon et al.,
2011, Mustapic et al., 2010). Muscimol dialysis was at concentrations of 0.5, 1.0, or 10.0 mM which is over the
range and duration others used in studies on awake and sleeping rats and piglets (Curran et al., 2001, Nattie and
Li, 2008, Taylor et al., 2006). Day studies were completed between 9 AM and 2 PM. Night studies were
completed between 7 P.M. and 2 A.M. A minimum of 36 h was allowed between consecutive studies on
individual goats.
Table 1. This table summarizes which studies each of the fifteen goats completed. Abbreviations are as follow: u
denotes unilateral dialysis, b denotes bilateral dialysis, L and R denote dialysis on the left and right side
respectively, and mCSF denotes mock cerebral spinal fluid.

2.4. Neurochemical analyses
To measure the amino acids glutamine (GLN), glycine (GLY) and GABA present in effluent dialysate reverse phase
high performance liquid chromatography was used as published by Muere et al. with fluorescent detection
using: Waters Resolve C18 column (150 × 3.9) and a fluorescent detector with excitation at 229 nm and emission
at 470 nm, β-alanine internal standard was used with O-phthaldialdehyde derivatization (Muere et al., 2013). To
measure 5-HT and its metabolite HIAA, an identical column was used but the potential was set at 0.6 V vs. an
Ag/AgCl reference electrode and a N-methylserotonin internal standard was used. A commercially available
assay (Enzo Life Sciences, Assay Designs 900-018, range 9.76–10,000 pg/mL) and a microplate reader at 405 nm
were used to determine SP levels. Measurement of norepinephrine, dopamine and their metabolites (DOPAC
and HVA) was accomplished by using a Waters μBondapak C18 column (300 × 3.9), potential setting of 0.65 V vs
Ag/AgCL reference electrode, and a 2, 5-dihydroxybenzylamine hydrobromide internal standard.
Microtubule location was determined both functionally and histologically. Functional determination was
accomplished via injections of N-methyl-d-aspartic acid (NMDA). The rationale for NMDA injections was based
on previous findings that glutamate receptor agonist injections into the preBötC elicits a tachypneic ventilatory
response (Krause et al., 2009b, McCrimmon et al., 2000, Solomon et al., 1999, Wenninger et al., 2004) thus, to
approximate microtubule placement relative to the preBötC, 500 nL injections were made of mCSF alone or
mixed with NMDA (100 mM). These injections were made in the awake state at least two weeks after
microtubule implantation when the goat had recovered from the surgery. Injection tubes were inserted only to
the distal end of the microtubule to avoid tissue damage. Breathing was monitored continuously during a 30min control period and over two hours during which, at 30 min intervals, either mCSF or NMDA was injected
unilaterally.
A post-mortem histological determination of microtubule location was also performed in each animal. The
cerebral circulation was isolated under deep anesthesia before flushing the brainstem with phosphate buffered
saline, followed by 4% paraformaldehyde in PBS following euthanasia. The brainstems were then extracted,
dehydrated in successive 20 and 30% sucrose solutions at 4 °C and then frozen (−80 °C). The brainstems were
serially sectioned at 25 μM in the transverse plane. One series was used for Nissl (cresyl violet) staining to
determine microtubule (MT) placement. Nissl-stained images (scanned resolution of 4000 dots/inch) of the
entire microtubule tract were captured (Nikon Super Coolscan 9000). Image software (Metamorph) was used to
calibrate and measure microtubule placement in millimeters (relative to the midline and the ventral medullary
surface) near the middle of the rostral-caudal MT damage range.

2.5. Data and statistical analyses
A pump with a known airflow rate was used to calibrate the inspiratory flow signal for breath by breath
calculation of V� I, f, VT, TI, TE and VT/TI, using custom designed software programs. The EEG and EOG signals were
utilized by a single investigator to score sleep state for each breath for night studies. Individual breath
ventilatory data were averaged into 5 and 15 min bins. For all ventilatory variables, metabolic rate (V� O2), arterial
blood gases, arterial blood pressure (BP), heart rate (HR), and rectal temperature (TR), a two-way repeated (RM)
measures ANOVA compared all drug (DAMGO or muscimol) doses to mCSF alone (one factor repetition with
dose and time as factors). Statistical analyses were over different portions of the predialysis period and 3-h
dialysis protocol. The interaction P values indicated whether there were statistically significant differences
between mCSF alone and mCSF mixed with drugs. For night studies, interaction term P values from two-way RM
ANOVAs (two factor repetition, state and time as factors) were performed to determine the effect of sleep state
on ventilatory variables. Statistical analyses were on absolute values for each variable and again for each

variable during hours 2 and 3 of the protocol expressed as a percent of the variable over the last 15 min of hour
1. Variability in ventilatory parameters was quantified using the coefficient of variation (CV). The CV was
determined for all breaths during 5 min intervals. A two-way RM ANOVA (with dose and time as factors) was
used to determine if significant interactions occurred resulting from DAMGO or muscimol dialysis. Holm-Sidak
post hoc tests were used where appropriate after each ANOVA.

2.6. Neurochemical analysis
For statistical analyses of neurochemical data, two-way RM ANOVAs (one factor repetition, dose and time as
factors) were used. The P values of the interaction term of ANOVA indicated whether the effect on effluent
neurochemical concentration over time of antagonist dialysis was significantly different from that of the timecontrol studies. This analysis was performed for SP, 5-HT, GLY, GABA, and norepinephrine for both muscimol and
DAMGO studies. Also, we computed the change in each neurochemical between pre and post dialysis of DAMGO
and muscimol, and then used a one-way ANOVA (drug as factor) to determine whether the neurochemicals
significantly changed.

3. Results
3.1. Placement of microtubules (MTs)
Shown in Fig. 1A and B are representative transverse sections of the goat medulla in which the location of the
distal end of the histologically identified microtubule tract is identified for each animal (represented by number).
The dialysis membrane extended 2 mm beyond (ventral) the dorsal-most aspect of the microtubule implantation
site. We did not measure drug diffusion in this study, but conservatively estimated an affected region (Fig. 1)
based on our previous dialysis studies in which we measured brain pH changes at two distances that resulted
from dialysis of CO2-enriched mCSF (Hodges et al., 2004). In that study, we measured a dose-dependent
decrease in extracellular fluid pH ∼220 μm from the dialysis probe when 25% or 80% CO2 was dialyzed, but
simultaneous measurements of pH at a distal brainstem site (∼1.4 mm) from the site of focal acidosis indicated
no detectable change in pH. Accordingly, we conservatively estimate a minimal diffusion of DAMGO to be
∼0.25 mm from the dialysis probe recognizing that others in rats have found greater DAMGO diffusion distance
(1.5–2.0 mm) from the dialysis probe (Montandon et al., 2011). We included a 2 × 1 mm gray box which
represents a minimal estimate of the affected brainstem region relative to the estimated location of the VRC
(circle). However, our model of pH changes with dialysis of acidified mCSF may underestimate the diffusion area
as the in vivo brainstem has great capacity to buffer protons but there is no comparable uptake of DAMGO.
As indicated in Table 1, we unilaterally dialyzed on both sides of the VRC in six goats and in four other goats,
unilateral dialysis was only on one side; thus, there were 16 sites of unilateral dialysis. Of these sixteen, eleven
were in the estimated affected regions. (Fig. 1A). Bilateral dialysis was in seven goats. Thirteen of the fourteen
estimated affected regions for the bilateral studies (Fig. 1B) reached the VRC.
As in past studies, we used the breathing frequency response to the glutamate receptor agonist NMDA as a
functional marker of proximity to the preBӧtC. We found breathing frequency increased at least 10% after
twenty-two of thirty-one NMDA injections made in the fifteen goats (insets Fig. 1A and B). In contrast, when
only mCSF was injected, breathing frequency increased more than 10% in only two of the thirty-one injections.
The variation in the responses to NMDA and the variation in histologically identified MT placement suggests that
the dialyzed receptor agonists likely were not restricted to the targeted preBötC or the VRC in all goats. This
possibility is a limitation of our study and will subsequently be discussed.

3.2. DAMGO microdialysis
There were no effects of time or dose (no significant interaction term; P > 0.05) in the two-way repeated (RM)
measures ANOVA comparing absolute values measured during unilateral dialyses of mCSF alone or three doses
of DAMGO (Table 2). Moreover, when the physiologic responses during and after unilateral DAMGO dialysis
were normalized to Hour 1 control values (immediately prior to DAMGO dialysis), there also was no significant
effects of time and dose for V� I, f, VT, (Fig. 2) or any other measured physiologic parameter. However, we noted a
consistent trend for a transient reduction in V� I during the final 30 min of 50 μM and 100 μM DAMGO dialyses.
The individual goat data suggested there were differences between goats in the time within this period when V� I
was reduced; thus, a moving time average was computed for 3 successive 5 min intervals, which is shown in Fig.
3. Using this approach, there was a significant difference in the V� I responses among mCSF dialysis and the 3
doses of DAMGO (P = 0.042) (one-way ANOVA, dose as factor). The post hoc test indicated that the response to
mCSF dialysis differed significantly from 50 μM DAMGO dialysis. Finally, dialysis of DAMGO destabilized
breathing (Fig. 4), where the coefficient of variation in f during and after the last 30 min of DAMGO dialysis was
significantly (P < 0.042) increased compared to mCSF dialysis.
Table 2. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral
dialysis of DAMGO into the ventral respiratory column of awake goats. Presented are data for four, fifteen
minute time periods for each of four studies (A–D). The first period of each study was predialysis control. During
the subsequent periods of all studies, mock cerebral spinal fluid (mCSF) was dialyzed. During period 3 of studies
B-D, DAMGO was added to the mCSF to provide concentration of 10 μM, 50 μM or 100 μM. Abbreviation of
physiologic variables are defined in the text. For all variables, there was no statistically significant (P > 0.05)
interaction value from the two-way repeated measures ANOVA (time and study as factors) comparisons of all 4
studies. For Study A n = 7, Study B & C n = 8, and Study D n = 9.

Fig. 2. Unilateral dialysis during the day of 100 μM DAMGO (n = 9, filled circles) did not significantly (P ≥ 0.758) alter
ventilation (V� I, panel A), breathing frequency (f, panel B) or tidal volume (VT, panel C) compared to dialysis of mCSF alone
(n = 7, open circles). Data are means ± SE. The x Axis is time from start of 180 min of dialysis. As indicated by the black line,
100 μM DAMGO was dialyzed between 60 and 120 min. The values shown during and after DAMGO dialyses are the
percent of the last 15 min prior to DAMGO dialyses. F and P values are the interaction term obtained from two-way
repeated measures ANOVA using time and dose as factors. Note the trend of a transient reduction in V� I and f over the last
30 min of DAMGO dialysis.

Fig. 3. Because of the trend of a transient reduction in V� I over the last 30 min of DAMGO dialysis (Fig. 2), a moving time
average was computed using 3 successive 5 min intervals and the lowest value for each goat over the last 30 min of
DAMGO dialysis and mCSF are plotted in this figure (filled circles). Average values for each dose of DAMGO are plotted
using mean symbols, data are means ± SE. One-way ANOVA indicated V� I as a percent of control differed significantly

(P < 0.042) over the 4 conditions shown. The post hoc test indicated the responses to 0 and 50 μM differed significantly
(P < 0.05).

Fig. 4. Visual inspection of ventilatory tracings indicates variability of breathing increased during and after unilateral dialysis
of 100 μM DAMGO. The four tracings were from a single goat for a portion of the last 15 min of the predialysis control
period (panel A) and the last 15 min of each of three hours of mCSF dialysis (panels B–D) with DAMGO increased during the
second of the three hours (Panel C).

There were significant (P < 0.05) effects of time and drug for V� I, f, TI TE, and VT/TI when comparing bilateral
dialysis of mCSF with bilateral dialysis of 100 μM DAMGO during the day. Expressing the data as absolute values
over the entire study protocol (Table 3), or when expressed as percent of control values immediately prior to
DAMGO dialysis (Fig. 5, Fig. 6), we found that bilateral dialysis of 100 μM DAMGO during the day significantly
(P < 0.05) increased V� I, f, TE, and VT/TI and decreased TI. Bilateral dialysis of DAMGO also destabilized breathing
(Fig. 7), where the coefficient of variation of V� I and f (Fig. 8) were significantly (P < 0.001) greater during the hour
after bilateral DAMGO dialysis compared to the hour after mCSF dialysis. There were no significant (P ≥ 0.516)
changes in any other measured variable during bilateral dialysis of DAMGO during the day (Table 3).
Table 3. Averages of raw values for physiologic variables obtained during studies testing the effect of bilateral
dialysis of DAMGO into the ventral respiratory column of awake goats. Presented are data for four, fifteen
minute time periods for each of two studies (A and B). The first period of each study was predialysis control.
During the subsequent three periods of both A and B studies, mock cerebral spinal fluid (mCSF) was dialyzed.
The only difference between A and B was in study B when DAMGO was added to the mCSF in period 3 to obtain
a concentration of 100 μM. Abbreviation of physiologic variables are defined in the text. Results of statistical
analyses using two-way repeated measures ANOVA (time and study as factors) indicated there was a significant
interaction term for V� I, (P = 0.025), f (P = 0.019), and TI (P = 0.007). There were significant (P < 0.05) effects of
time indicated as follows: * 4 differed from 1, ** 4 differed from 1 and 2, and ***1 differed from 2, 3, & 4. For
Studies A & B n = 7.

Fig. 5. Bilateral dialysis of 100 μM DAMGO during the day (filled circles, n = 7) significantly (P < 0.002) increased ventilation
(V� I, panel A) and breathing frequency (f, panel B) but did not alter (P < 0.446) tidal volume (VT, panel C) compared to dialysis
of mCSF alone (open circles, n = 7). Data are means ± SE. Dialysis of 100 μM DAMGO occurred between 60 and 120 min
(indicated by solid line). The values shown during and after DAMGO dialyses are the percent of the last 15 min prior to
DAMGO dialyses. The F and P values are interaction terms from two-way repeated measures ANOVA using dose and time as
factors. Asterisks denote values different between open and closed symbols ((P < 0.05), post hoc test).

Fig. 6. Inspiratory time (TI), expiratory time (TE) and tidal volume/inspiratory time changed differently between bilateral
dialysis of DAMGO (left panels) and unilateral dialysis of muscimol (right panel). Data are means ± SE. Bilateral dialysis of
100 μM DAMGO (n = 7) during the day significantly (P < 0.001) decreased TI, increased TE during the post DAMGO dialyses
period, and increased VT/TI during and after DAMGO dialysis. TI and VT/TI increased after muscimol dialysis while TE was
significantly (P < 0.001) decreased during and after muscimol dialysis. Filled circles indicate studies during which 100 μM
DAMGO was dialyzed during 60–120 min (solid line indicates period of DAMGO dialysis). Two-way repeated measures
ANOVA was used to obtain F and P values and values shown are the interaction term of the ANOVA. Asterisks denote values
different between open and closed symbols (P < 0.05, post hoc test).

Fig. 7. Visual inspection of ventilatory tracings indicates variability of breathing increased and inspiratory time decreased
during and after bilateral dialysis of 100 μM DAMGO. The four tracings were from a single goat for a portion of the last
15 min of the predialysis control period (panel A) and the last 15 min of each of three hours of mCSF dialysis (panels B–D)
with DAMGO increased during the second of the three hours (Panel C).

Fig. 8. The coefficient of variation of ventilation (V� I, panel A) and breathing frequency (f, panel B) within 5 min periods was
significantly (P < 0.001) greater during the period after bilateral 100 μM DAMGO dialysis than after bilateral mCSF dialysis.
Data are means ± SE. The x Axis is time from start of 180 min of dialysis. As indicated by the black line, DAMGO was dialyzed
between 60 and 120 min. The F and P values are interaction terms from two-way repeated measures ANOVA using dose
and time as factors. Asterisks denote values different between open and closed symbols (P < 0.05, post hoc test).

At night, for unilateral and bilateral (Fig. 9) dialysis of 100 μM DAMGO, there were no significant interaction
terms in two-way ANOVA analysis (time and state as factors) when comparing responses during awake and
NREM sleep (Table 4, Table 5).

Fig. 9. During bilateral dialysis of 100 μM DAMGO (n = 7) at night, there were no significant (P ≥ 0.348) interaction terms for
any ventilatory variable of the two-way ANOVA comparing awake and NREM sleep (state and time). Data are means ± SE.
Data from each state were averaged in 15 min bins, the filled circles indicate the awake state and open circles indicate the
NREM sleep state. Dialysis of 100 μM DAMGO occurred during minutes 60–120 of the study and is indicated by the solid
line.

Table 4. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral
dialysis of DAMGO into the ventral respiratory column of goats during awake and NREM sleep states. Presented
are data for the last fifteen minutes of three hours of mCSF dialysis. During the second hour, DAMGO was added
to the mCSF to provide a concentration of 100 μM. Abbreviation of physiologic variables are defined in the text.
Ventilatory data were obtained on seven goats, but HR, BP, blood gases, and pH were obtained on only four
goats. For all variables, there was no statistically significant (P > 0.05) interaction value from the two-way
repeated measures ANOVA (time and study as factors) comparing awake and NREM sleep.

Table 5. Average of raw values for physiologic variables obtained during studies testing the effect of bilateral dialysis of
DAMGO into the ventral respiratory column of goats during awake and NREM sleep states. Presented are data for the last
fifteen minutes of three hours of mCSF dialysis. During the second hour, DAMGO was added to the mCSF to provide a
concentration of 100 μM. Abbreviation of physiologic variables are defined in the text. For all variables, there was no
statistically significant (P > 0.05) interaction value from the two-way repeated measures ANOVA (time and study as factors)
comparisons of all 4 studies. Ventilatory data were obtained on seven goats, but HR, BP, blood gases, and pH were only
obtained on four goats.

During daytime unilateral DAMGO dialysis, a one-way ANOVA analysis of the change in GABA between pre and
post dialysis of DAMGO indicated there was a significant (P < 0.020) decrease in GABA during dialysis of 50 μM
and 100 μM DAMGO (Fig. 10). In addition, during both unilateral and bilateral dialysis of 100 μM DAMGO at
night, there were significant (P < 0.001) decreases in GABA in the effluent mCSF. However, bilateral dialysis of
100 μM DAMGO during the day did not significantly (P > 0.05) alter GABA. Lastly, there were no significant
changes (P > 0.05) in 5-HT, SP, glutamine, glycine, dopamine, norepinephrine and the metabolites DOPAC, HIAA,
and HVA in the effluent dialysate during DAMGO dialyses studies (data not shown).

Fig. 10. Unilateral dialysis of 50 μM and 100 μM DAMGO during the day significantly (P < 0.02) decreased GABA in the
effluent dialyzed mCSF. Data are means ± SE. On the x-axis are the DAMGO doses and y axis indicates the change in GABA
between hours 1 and 3 of dialysis. Statistical analysis was by one-way ANOVA (drug as factor).

3.3. Muscimol microdialysis
A two-way ANOVA (time and dose as factors) indicated there were no significant (P > 0.05) differences in
absolute values of physiologic variables between mCSF dialysis and dialysis of three muscimol concentrations
(0.5, 1.0, or 10 mM) (Table 6). However, when variables during and after muscimol dialysis were expressed as a
percent of the periods just prior to muscimol dialysis, there were significant effects of time and dose for V� I
(P < 0.025) and f (P < 0.044) when all muscimol doses were compared and when each elevated muscimol
concentration was individually compared to the mCSF study (Fig. 11, 1.0 mM shown). Expressed as percent
change, only 0.5 mM muscimol significantly (P < 0.005) altered VT. All doses of muscimol significantly (P < 0.023)
decreased TE but did not significantly (P ≥ 0.577) alter TI or VT/TI (Fig. 6).
Table 6. Average of raw values for physiologic variables obtained during studies testing the effect of unilateral
dialysis of muscimol into the ventral respiratory column of awake goats. Presented are data for four, fifteen
minute time periods for each of four studies (A–D). The first period of each study was predialysis control. During
the subsequent periods of all studies, mock cerebral spinal fluid (mCSF) was dialyzed. During period 3 of studies
B–D, muscimol was added to the mCSF to provide concentrations of 0.5 μM, 1.0 μM or 10 μM respectively.
Abbreviation of physiologic variables are defined in the text. For all variables, there was no statistically
significant (P > 0.05) interaction value from the two-way repeated measures ANOVA (time and study as factors)
comparisons of all 4 studies. For studies A–C n = 7, study D n = 6.

Fig. 11. Unilateral dialysis of 1.0 mM (n = 7) muscimol (filled circles) during the day significantly increased ventilation (V� I,
panel A, P = 0.025) and breathing frequency (f, panel B, P = 0.044) but did not alter tidal volume (VT, panel C, P = 0.196)
compared to dialysis of mCSF alone (open circles) (n = 7). Data are means ± SE. The solid lines indicate the period during
which muscimol was dialyzed (60–120 min). Two-way repeated measures ANOVA was used (dose and time as factors) to
obtain F and P values. Asterisks denote values significantly different between open and closed symbols (P < 0.05, post hoc
test).

The highest concentration of muscimol (10.0 mM) induced varied degrees of behavioral excitability, nystagmus,
spastic limb movements, and postural instability lasting up to 4 h following the completion of studies. In 3 of 9
studies, these behavioral effects were too severe to warrant continuation of the study beyond the second hour.
Two of the three animals had a dramatic increase in f accompanied by severe behavioral effects, while the third
animal’s breathing frequency decreased eventually leading to terminal apnea. Despite these major behavioral
changes, there were no significant changes during or after muscimol dialysis in all neurochemicals analyzed in
the effluent mCSF, although norepinephrine increased in 4 of 6 goats during dialysis of 10.0 mM muscimol (data
not shown). For all doses of muscimol, there were no significant (P ≥ 0.094) changes in PaO2, PaCO2, BP, HR, TR,
or V� O2 (Table 6).

4. Discussion
Microdialysis of antagonists to excitatory, neuromodulatory, G protein-coupled receptors into the VRC of awake
and sleeping goats (Langer et al., 2016, Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b, Muere et
al., 2015c) support the concept of neuromodulator compensation, whereby decreases in excitatory receptor
activity are compensated by increases in other (predominantly excitatory) neuromodulators to prevent a
decrease in ventilation and breathing frequency (Doi and Ramirez, 2008, Doi and Ramirez, 2010). In other words,
there is “compensation” defined as no change in ventilation with dialysis of excitatory antagonists and that this
may be due to the observed concomitant increase in excitatory (SP) and decrease in inhibitory
neurotransmitters (GABA).
The objective herein was to determine whether compensation would also occur during VRC dialyses of agonists
to inhibitory, G protein-coupled (μ-opioid) or inhibitory, ionotropic (GABAA) receptors in awake and sleeping
goats. Ventilatory data indicated that what appears to be compensation occurred during dialysis of both types of
inhibitory receptor agonists. Furthermore, it appears the compensation in neuromodulators differed between
agonists to inhibitory G protein-coupled (μ-opioid) receptors and agonists of inhibitory ionotropic (muscimol)
receptors.

4.1. Ventilatory and neurochemical effects of opioids dialyzed into the VRC
μ-opioid receptors are widely and abundantly expressed throughout respiratory control regions in the
brainstem, including the preBötC region of the VRC (Gray et al., 1999, Haji et al., 2003, Krause et al., 2009a,
Pattinson, 2008, Stornetta et al., 2003). These inhibitory, neuromodulatory receptors may contribute to the
regulation of normal eupneic ventilation through the activity of endogenous opioids. The activation of these
receptors also contributes to unwanted depression of ventilation with opiate use clinically, or cardiorespiratory
failure in cases of opiate abuse/overdose. Previous studies have addressed the effects of exogenously applied
opioid receptor agonists within the neural networks that control breathing, but these studies show inconsistent
effects on ventilatory variables (Krause et al., 2009a, Lalley, 2008, Montandon et al., 2011, Mustapic et al., 2010,
Pattinson, 2008). Montandon et al. dialyzed DAMGO into the preBötC of awake and anesthetized rats and found
that breathing frequency was depressed at low concentrations, and found complete apnea at higher
concentrations (Montandon et al., 2011). In contrast, Mustapic et al. reported that the injection of DAMGO into
the preBötC of decerebrate (unanesthetized) dogs increased breathing frequency and phrenic nerve output
(Mustapic et al., 2010). Different still were studies by Krause et al., in which DAMGO bilaterally injected into the
preBötC of awake goats did not affect respiratory rhythm or pattern while breathing room air (Krause et al.,
2009a). Our current results differ from each of the above as unilateral DAMGO dialysis decreased ventilation,
but bilateral dialysis increased ventilation, breathing frequency and ventilatory drive while it decreased
inspiratory time. In addition, both unilateral and bilateral dialysis of DAMGO destabilized breathing frequency,

which is similar to previous reports that opioids can cause increased variability or destabilization of breathing
(Mitsis et al., 2009, Pattinson, 2008, van den Aardweg, 2009, Walker et al., 2007). Collectively, these data
suggest that the effect of opioids on ventilation might differ between species, state of wakefulness, and the
nature of the experimental preparation.
During unilateral DAMGO dialysis, a local decrease in GABA (as indicated in the collected effluent mCSF, Fig. 10)
may have provided neuromodulatory compensation for a presumed DAMGO-induced depression of ventilation
(Fig. 3). In other words, an initial direct depression of ventilation (Fig. 3) by DAMGO may have been offset within
minutes by a secondary/compensatory decrease in GABA or by a change in another neurochemical to return
ventilation to normal. This secondary/compensatory response may have been relatively greater with 100 μM
compared to 50 μM which is why a significant depression in ventilation was found with 50 μM but not 100 μM
DAMGO. A secondary/compensatory response is sufficiently rapid to prevent a detectable decrease in
ventilation during dialysis of antagonists to excitatory neuromodulator receptors (Muere et al., 2013, Muere et
al., 2015a, Muere et al., 2015b, Muere et al., 2015c). Compensation during DAMGO dialysis may also have been
within the contralateral VRC. However, findings herein (Fig. 5) do not support this possibility as bilateral DAMGO
dialysis increased ventilation. This finding is similar to bilateral dialysis of antagonists to excitatory receptors
which also increased ventilation even though ventilation did not change during unilateral dialysis of these
antagonists (Langer et al., 2016). Accordingly, during unilateral and bilateral dialysis, there likely are multiple
factors affecting ventilation, which makes it difficult to measure a steady-state, maximal effect, or recovery
effect. The cause of the increased ventilation with bilateral DAMGO was not associated with decreased GABA;
thus, we speculate it is due to other mechanisms such as increases in excitatory neuromodulators not yet
measured and/or changes in second messengers downstream of G protein-coupled neuromodulator receptors.
We have no explanation for why the increased ventilation with bilateral DAMGO dialysis did not result in arterial
hypocapnia even though metabolic rate did not change. Nevertheless, whatever the exact mechanism of the
neurochemical response to perturbation of neuromodulator receptors, it does not appear unique to awake and
NREM sleep states as Langer et al. found increases in 5-HT and SP equal in awake and anesthetized goats during
dialysis of 50 mM atropine (Langer et al., 2016).
Opioids administered clinically in humans for pain management clearly cause respiratory depression, and when
given intravenously likely simultaneously depress multiple respiratory nuclei (Pattinson, 2008). Why does
neuromodulator compensation not prevent this respiratory depression? It is not known whether
neuromodulator compensation is widespread throughout the brain. Thus, the specific neural sites providing a
tonic drive to breathe (chemoreceptors) and/or sites of respiratory-associated motor neurons (such as the
hypoglossal nuclei) might not display neuromodulator compensation during opiate-induced depression, and
thus could be the major substrate for respiratory depression during clinical intravenous opioid administration.
Indeed opioid respiratory depression has been linked to increased incidence of obstructive sleep apnea and
sleep disordered breathing (Randerath and George, 2012, Zutler and Holty, 2011), which as reported by Skulsky
et al. (Skulsky et al., 2007) and Hajiha et al. (Hajiha et al., 2009) could be due to opioid depression of hypoglossal
muscle activity.
In reduced preparations opioids added to a perfusate of the medulla induced a quantal or step-wise, rather than
progressive, slowing of respiratory frequency (Mellen et al., 2003). In awake goats quantal slowing does not
occur during opioid administration to the VRC (which includes the preBötC). These findings suggest a
fundamental difference in the effects of opioids between reduced and intact preparations. Indeed, an index of
the drive to breathe (VT/TI) was increased during bilateral μ-opioid receptor stimulation, which likely represents
the effects of compensation (or overcompensation) by neuromodulators. Moreover, the present findings
demonstrate a fundamental difference between the effects of DAMGO and muscimol on respiratory drive and
timing mechanisms.

4.2. Ventilatory and neurochemical effects of unilateral muscimol dialysis in the VRC
The current and past dialysis studies in unanesthetized goats found neuromodulator compensation during
perturbation of G protein-coupled receptors (Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b,
Muere et al., 2015c). Herein we found what could be interpreted as overcompensation for increases in
inhibitory ionotropic GABA receptor activity during muscimol dialysis. Several previous studies (Akilesh et al.,
1997, Curran et al., 2000, Curran et al., 2001, Darnall et al., 2001, Gatti et al., 1987, Yamada et al., 1981, Yamada
et al., 1982) found that administering muscimol to various brainstem regions depressed breathing and/or
arousal from sleep. On the other hand, other studies (Nattie and Li, 2008, Taylor et al., 2006) found that
administration of muscimol increased breathing and/or increased the ventilatory response to CO2 and hypoxia
(Nattie and Li, 2000, Taylor et al., 2006). Our findings are similar to these latter studies as we found that
muscimol dialysis increased ventilation and breathing frequency.
We found no significant change in the levels of any measured neurochemicals in the effluent mCSF that could
counter a depressant effect of muscimol on neuronal activity. However, 10.0 mM muscimol dialysis increased
norepinephrine in effluent dialysate in 4 of 6 goats, which could have contributed to the increased V� I in these
goats. A mechanism of GABA receptor-mediated increase in norepinephrine release has been proposed by
Scatton and Bartholini, 1981 who found that administration of a GABA receptor agonist (Progabide) in the rat
hypothalamus activated noradrenergic neurons and increased norepinephrine turnover (Scatton and Bartholini,
1981). Another possible explanation is that muscimol acts on presynaptic GABA receptors to increase glutamate
release and postsynaptic neuronal activity (Jang et al., 2006, Koga et al., 2005); thus, presynaptic, GABAmediated glutamate responses may contribute to the increased V� I and f for all doses of muscimol. The
behavioral effects observed with muscimol dialysis could also be due to increased glutamate release, as these
effects were similar to those observed by Wenninger et al. after injection of ibotenic acid (an excitatory
neurotoxin which acts glutamate receptors) into the preBötC of goats (Wenninger et al., 2004).
Irrespective of the mechanism and/or pathway, the ventilatory responses to muscimol indicate that some type
of compensation and/or secondary effect exists to prevent respiratory depression during perturbations of
inhibitory ionotropic receptors, which instead increased ventilation in the behaving goat.

4.3. μ-Opioid and GABA receptor-mediated breathing instabilities
There was significant ventilatory instability with dialyses of the μ-opioid receptor agonist (Figs. 4, 7, 8) and to
some degree during muscimol dialysis. This instability contrasts to studies (Langer et al., 2016, Muere et al.,
2013, Muere et al., 2015a, Muere et al., 2015b, Muere et al., 2015c) in which dialyses of antagonists to multiple
excitatory receptors in the VRC did not destabilize breathing. The destabilization with DAMGO could be due to
time-dependent changes in the direct effect of opioid-induced depression and the indirect effect of potential
compensatory mechanisms. Or a compensatory increase in an unknown excitatory neuromodulator may have
created a “high-gain controller”, which destabilizes breathing (Asyali et al., 2002, Khoo, 2000). Finally,
destabilization in the muscimol studies could be due to increased norepinephrine which during pathological
states induced increased variability in breathing (Viemari et al., 2013, Zanella et al., 2014).

5. Caveats and limitations
We previously summarized (Muere et al., 2013, Muere et al., 2015a, Muere et al., 2015b, Muere et al., 2015c)
the limitations and caveats of dialyses studies in the medulla of awake and sleeping goats. One limitation is that

the microtubules were not all implanted at the same site (Fig. 1). The variation in placement was due primarily
to the need for avoiding blood vessels on the dorsal surface during surgical implantation. A second limitation is
the uncertainty of the exact boundaries of the targeted preBötC. To assess the proximity of the microtubule to
the preBötC, we utilize the ventilatory response to the glutamate receptor agonist NMDA. Herein, there was a
positive response to NMDA even in some goats (see # 11 and 15) whose post mortem histologic measurements
indicated the microtubule was outside the estimated boundaries of the preBötC; thus, it is possible our
anatomic estimate of the preBötC may be too restrictive. A third limitation is the study may have been under
powered which could be why we did not detect a significant depression of ventilation with 100 μM unilateral
dialysis of DAMGO even though there was a significant depression with 50 μM unilateral dialysis of DAMGO. A
fourth limitation is uncertainty regarding the diffusion of the drugs dialyzed. A final limitation is that we
currently only have the capability of measuring the selected neurochemicals in the effluent mCSF, and as a result
we likely missed potential changes in other local neuromodulatory molecules.

6. Summary and conclusions
We found that: (1) V� I decreased during unilateral but increased during bilateral dialysis of DAMGO, (2) dialyses
of DAMGO destabilized breathing, (3) unilateral dialysis of muscimol increased breathing and (4) dialysis of
DAMGO decreased GABA in the effluent mCSF. We conclude: (1) neuromodulatory compensation can occur
during altered inhibitory neuromodulator receptor activity, and (2) the mechanism of compensation differs
between G protein-coupled excitatory and inhibitory receptors and between G protein-coupled and ionotropic
inhibitory receptors, and (3) the effects of presumed perturbations of inhibitory receptor activity within the
respiratory control network shown herein likely have general applicability to neuronal networks throughout the
brain.

Author contributions
T.L. performed surgeries and experiments, analyzed data and wrote the MS, S.E.N. performed surgeries and
experiments and histological analyses, contributed to data analysis and figures, and MS editing, N.J.B. performed
experiments and contributed to intellectual discussions, S.T. performed experiments and contributed to data
analysis and histological analyses, L.P. performed all surgeries, M.R.H. contributed to intellectual discussions, MS
writing and editing, H.V.F. contributed to intellectual discussions and MS writing and editing. Funding for this
study was provided by NIH HL 112996 and HL-007852 and the Veterans Administration. All experiments were
performed at Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A.

Disclosures
There are no conflicts of interest to disclose.

References

1 M.R. Akilesh, M. Kamper, A. Li, E.E. Nattie. Effects of unilateral lesions of retrotrapezoid nucleus on breathing
in awake rats, J. Appl. Physiol., 82 (1997), pp. 469-479
2 M.H. Asyali, R.B. Berry, M.C. Khoo. Assessment of closed-loop ventilatory stability in obstructive sleep apnea,
IEEE Trans. Biomed. Eng., 49 (2002), pp. 206-216
3 A.K. Curran, G. Chen, R.A. Darnall, J.J. Filiano, A. Li, E.E. Nattie. Lesion or muscimol in the rostral ventral
medulla reduces ventilatory output and the CO(2) response in decerebrate piglets, Respir. Physiol.,
123 (2000), pp. 23-37
4 A.K. Curran, R.A. Darnall, J.J. Filiano, A. Li, E.E. Nattie. Muscimol dialysis in the rostral ventral medulla reduced
the CO(2) response in awake and sleeping piglets, J. Appl. Physiol., 90 (2001), pp. 971-980
5 R.A. Darnall, A.K. Curran, J.J. Filiano, A. Li, E.E. Nattie. The effects of a GABA(A) agonist in the rostral ventral
medulla on sleep and breathing in newborn piglets, Sleep, 24 (2001), pp. 514-527
6 A. Doi, J.M. Ramirez. Neuromodulation and the orchestration of the respiratory rhythm, Respir. Physiol.
Neurobiol., 164 (2008), pp. 96-104
7 A. Doi, J.M. Ramirez. State-dependent interactions between excitatory neuromodulators in the neuronal
control of breathing, J. Neurosci., 30 (2010), pp. 8251-8262
8 P.J. Gatti, A.M. DaSilva, R.A. Gillis. Cardiorespiratory effects produced by injecting drugs that affect GABA
receptors into nuclei associated with the ventral surface of the medulla, Neuropharmacology, 26
(1987), pp. 423-431
9 P.A. Gray, J.C. Rekling, C.M. Bocchiaro, J.L. Feldman. Modulation of respiratory frequency by peptidergic
input to rhythmogenic neurons in the preBotzinger complex, Science, 286 (1999), pp. 1566-1568
10 A. Haji, M. Okazaki, Y. Ohi, H. Yamazaki, R. Takeda. Biphasic effects of morphine on bulbar respiratory
neuronal activities in decerebrate cats, Neuropharmacology, 45 (2003), pp. 368-379
11 M. Hajiha, M.A. DuBord, H. Liu, R.L. Horner. Opioid receptor mechanisms at the hypoglossal motor pool and
effects on tongue muscle activity in vivo, J. Physiol., 587 (2009), pp. 2677-2692
12 M.R. Hodges, L. Klum, T. Leekley, D.T. Brozoski, J. Bastasic, S. Davis, J.M. Wenninger, T.R. Feroah, L.G. Pan,
H.V. Forster. Effects on breathing in awake and sleeping goats of focal acidosis in the medullary raphe,
J. Appl. Physiol., 96 (2004), pp. 1815-1824
13 I.S. Jang, M. Nakamura, Y. Ito, N. Akaike. Presynaptic GABAA receptors facilitate spontaneous glutamate
release from presynaptic terminals on mechanically dissociated rat CA3 pyramidal neurons,
Neuroscience, 138 (2006), pp. 25-35
14 M.C. Khoo. Determinants of ventilatory instability and variability, Respir. Physiol., 122 (2000), pp. 167-182
15 H. Koga, H. Ishibashi, H. Shimada, I.S. Jang, T.Y. Nakamura, J. Nabekura. Activation of presynaptic GABAA
receptors increases spontaneous glutamate release onto noradrenergic neurons of the rat locus
coeruleus, Brain Res., 1046 (2005), pp. 24-31
16 K.L. Krause, S.E. Neumueller, B.D. Marshall, T. Kiner, J.M. Bonis, L.G. Pan, B. Qian, H.V. Forster. Micro-opioid
receptor agonist injections into the presumed pre-Botzinger complex and the surrounding region of
awake goats do not alter eupneic breathing, J. Appl. Physiol., 107 (2009), pp. 1591-1599
17 K.L. Krause, S.E. Neumueller, B.D. Marshall, T. Kiner, J.M. Bonis, L.G. Pan, B. Qian, H.V. Forster. Normal
breathing pattern and arterial blood gases in awake and sleeping goats after near total destruction of
the presumed pre-Botzinger complex and the surrounding region
18 J. Appl. Physiol., 106 (February (2)) (2009), pp. 605-619, 10.1152/japplphysiol.90966.2008, PMID:19095752

19 P.M. Lalley. Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for
involvement in certain types of ventilatory disturbances, Am. J. Physiol. Regul. Integr. Comp. Physiol.,
285 (2003), pp. R1287-R1304
20 P.M. Lalley. Opioidergic and dopaminergic modulation of respiration, Respir. Physiol. Neurobiol., 164 (2008),
pp. 160-167
21 T.M. Langer 3rd, S.E. Neumueller, E. Crumley, N.J. Burgraff, S. Talwar, M.R. Hodges, L.G. Pan, H.V. Forster.
State-dependent and -independent effects of dialyzing excitatory neuromodulator receptor
antagonists into the ventral respiratory column, J. Appl. Physiol. (2016), (1985), jap 00619 02016
22 D.R. McCrimmon, A. Monnier, F. Hayashi, E.J. Zuperku. Pattern formation and rhythm generation in the
ventral respiratory group, Clin. Exp. Pharmacol. Physiol., 27 (2000), pp. 126-131
23 N.M. Mellen, W.A. Janczewski, C.M. Bocchiaro, J.L. Feldman. Opioid-induced quantal slowing reveals dual
networks for respiratory rhythm generation, Neuron, 37 (2003), pp. 821-826
24 G.D. Mitsis, R.J. Governo, R. Rogers, K.T. Pattinson. The effect of remifentanil on respiratory variability,
evaluated with dynamic modeling, J. Appl. Physiol., 106 (2009), pp. 1038-1049, (1985)
25 G. Montandon, R. Horner. Rebuttal from gaspard montandon and richard horner, J. Physiol., 592 (2014), p.
1167
26 G. Montandon, W. Qin, H. Liu, J. Ren, J.J. Greer, R.L. Horner. PreBotzinger complex neurokinin-1 receptorexpressing neurons mediate opioid-induced respiratory depression, J. Neurosci., 31 (2011), pp. 12921301
27 C. Muere, S. Neumueller, J. Miller, S. Olesiak, M.R. Hodges, L. Pan, H.V. Forster. Atropine microdialysis within
or near the pre-Botzinger complex increases breathing frequency more during wakefulness than
during NREM sleep, J. Appl. Physiol., 114 (2013), pp. 694-704
28 C. Muere, S. Neumueller, J. Miller, S. Olesiak, M.R. Hodges, L. Pan, H.V. Forster. Evidence for respiratory
neuromodulator interdependence after cholinergic disruption in the ventral respiratory column,
Respir. Physiol. Neurobiol., 205 (2015), pp. 7-15
29 C. Muere, S. Neumueller, S. Olesiak, J. Miller, T. Langer, M.R. Hodges, L. Pan, H.V. Forster. Combined
unilateral blockade of cholinergic, peptidergic, and serotonergic receptors in the ventral respiratory
column does not affect breathing in awake or sleeping goats, J Appl Physiol, 119 (2015), pp. 308-320,
(1985)
30 C. Muere, S.E. Neumueller, S.J. Olesiak, J.R. Miller, M.R. Hodges, L.G. Pan, H.V. Forster. Blockade of
neurokinin-1 receptors in the ventral respiratory column does not affect breathing but alters
neurochemical release, J. Appl. Physiol., 118 (2015), pp. 732-741
31 S. Mustapic, T. Radocaj, A. Sanchez, Z. Dogas, A.G. Stucke, F.A. Hopp, E.A. Stuth, E.J. Zuperku. Clinically
relevant infusion rates of mu-opioid agonist remifentanil cause bradypnea in decerebrate dogs but
not via direct effects in the pre-Botzinger complex region, J. Neurophysiol., 103 (2010), pp. 409-418
32 E. Nattie, A. Li. Muscimol dialysis in the retrotrapezoid nucleus region inhibits breathing in the awake rat, J.
Appl. Physiol., 89 (2000), pp. 153-162
33 E. Nattie, A. Li. Muscimol dialysis into the caudal aspect of the Nucleus tractus solitarii of conscious rats
inhibits chemoreception, Respir. Physiol. Neurobiol., 164 (2008), pp. 394-400
34 K.T. Pattinson. Opioids and the control of respiration, Br. J. Anaesth., 100 (2008), pp. 747-758
35 W.J. Randerath, S. George. Opioid-induced sleep apnea: is it a real problem?, J. Clin. Sleep Med., 8 (2012),
pp. 577-578
36 B. Scatton, G. Bartholini. Drug-induced changes of epinephrine turnover in the rat hypothalamus, Life Sci.,
29 (1981), pp. 1161-1170

37 E.M. Skulsky, N.I. Osman, H.A. Baghdoyan, R. Lydic. Microdialysis delivery of morphine to the hypoglossal
nucleus of Wistar rat increases hypoglossal acetylcholine release, Sleep, 30 (2007), pp. 566-573
38 I.C. Solomon, N.H. Edelman, J.A. Neubauer. Patterns of phrenic motor output evoked by chemical
stimulation of neurons located in the pre-Botzinger complex in vivo, J. Neurophysiol., 81 (1999), pp.
1150-1161
39 R.L. Stornetta, C.P. Sevigny, P.G. Guyenet. Inspiratory augmenting bulbospinal neurons express both
glutamatergic and enkephalinergic phenotypes, J. Comp. Neurol., 455 (2003), pp. 113-124
40 N.C. Taylor, A. Li, E.E. Nattie. Ventilatory effects of muscimol microdialysis into the rostral medullary raphe
region of conscious rats, Respir. Physiol. Neurobiol., 153 (2006), pp. 203-216
41 N.J. Tillakaratne, L. Medina-Kauwe, K.M. Gibson. gamma-Aminobutyric acid (GABA) metabolism in
mammalian neural and nonneural tissues, Comp. Biochem. Physiol. A Physiol., 112 (1995), pp. 247-263
42 J.G. van den Aardweg. Respiratory variability after opioids: see it happen, J. Appl. Physiol., 106 (2009), pp.
1029-1030, (1985)
43 J.C. Viemari, A.J. Garcia 3rd, A. Doi, G. Elsen, J.M. Ramirez. beta-Noradrenergic receptor activation
specifically modulates the generation of sighs in vivo and in vitro, Front. Neural Circuits, 7 (2013), p.
179
44 J.M. Walker, R.J. Farney, S.M. Rhondeau, K.M. Boyle, K. Valentine, T.V. Cloward, K.C. Shilling. Chronic opioid
use is a risk factor for the development of central sleep apnea and ataxic Breathing, J. Clin. Sleep Med.,
3 (2007), 455-+
45 J.M. Wenninger, L.G. Pan, L. Klum, T. Leekley, J. Bastastic, M.R. Hodges, T.R. Feroah, S. Davis, H.V. Forster.
Large lesions in the pre-Botzinger complex area eliminate eupneic respiratory rhythm in awake goats,
J. Appl. Physiol., 97 (2004), pp. 1629-1636
46 K.A. Yamada, P. Hamosh, R.A. Gillis. Respiratory depression produced by activation of GABA receptors in
hindbrain of cat, J. Appl. Physiol. Respir. Environ. Exerc. Physiol., 51 (1981), pp. 1278-1286
47 K.A. Yamada, W.P. Norman, P. Hamosh, R.A. Gillis. Medullary ventral surface GABA receptors affect
respiratory and cardiovascular function, Brain Res., 248 (1982), pp. 71-78
48 S. Zanella, A. Doi, A.J. Garcia 3rd, F. Elsen, S. Kirsch, A.D. Wei, J.M. Ramirez. When norepinephrine becomes a
driver of breathing irregularities: how intermittent hypoxia fundamentally alters the modulatory
response of the respiratory network, J. Neurosci., 34 (2014), pp. 36-50
49 M. Zutler, J.E. Holty. Opioids, sleep, and sleep-disordered breathing, Curr. Pharm. Des., 17 (2011), pp. 14431449

